Cidara Therapeutics (CDTX) Invested Capital: 2017-2025
Historic Invested Capital for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $422.4 million.
- Cidara Therapeutics' Invested Capital rose 263.29% to $422.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.4 million, marking a year-over-year increase of 263.29%. This contributed to the annual value of $163.9 million for FY2024, which is 2309.55% up from last year.
- Cidara Therapeutics' Invested Capital amounted to $422.4 million in Q3 2025, which was down 15.72% from $501.2 million recorded in Q2 2025.
- Over the past 5 years, Cidara Therapeutics' Invested Capital peaked at $501.2 million during Q2 2025, and registered a low of -$18.2 million during Q2 2022.
- In the last 3 years, Cidara Therapeutics' Invested Capital had a median value of $116.3 million in 2024 and averaged $133.1 million.
- Over the last 5 years, Cidara Therapeutics' Invested Capital had its largest YoY gain of 5,346.21% in 2024, and its largest YoY loss of 212.67% in 2024.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Invested Capital stood at $24.2 million in 2021, then plummeted by 159.75% to -$14.4 million in 2022, then spiked by 48.63% to -$7.4 million in 2023, then spiked by 2,309.55% to $163.9 million in 2024, then surged by 263.29% to $422.4 million in 2025.
- Its Invested Capital stands at $422.4 million for Q3 2025, versus $501.2 million for Q2 2025 and $141.7 million for Q1 2025.